Pathways and mechanisms of venetoclax resistance
P Bose, V Gandhi, M Konopleva - Leukemia & lymphoma, 2017 - Taylor & Francis
The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
Tumour heterogeneity encompasses both the malignant cells and their microenvironment.
While heterogeneity between individual patients is known to affect the efficacy of cancer …
While heterogeneity between individual patients is known to affect the efficacy of cancer …
Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions
XS Puente, P Jares, E Campo - Blood, The Journal of the …, 2018 - ashpublications.org
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are 2 well-defined
entities that diverge in their basic pathogenic mechanisms and clinical evolution but they …
entities that diverge in their basic pathogenic mechanisms and clinical evolution but they …
Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies
L Ondrisova, M Mraz - Frontiers in oncology, 2020 - frontiersin.org
The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the
therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell …
therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell …
BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor
Bromodomain and extra-terminal (BET) family proteins are key regulators of gene
expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved …
expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved …
Plant secondary metabolites as feed additives in calves for antimicrobial stewardship
Irrational usage of antibiotic feed additives in livestock industry, especially as growth
promoters, has become a global challenge due to the unintended zoonotic impact through …
promoters, has become a global challenge due to the unintended zoonotic impact through …
The immunology of DLBCL
T Takahara, S Nakamura, T Tsuzuki, A Satou - Cancers, 2023 - mdpi.com
Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common type of
malignant lymphoid neoplasm and includes morphologically and molecularly …
malignant lymphoid neoplasm and includes morphologically and molecularly …
Macrophage-and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo
C Martines, S Chakraborty, M Vujovikj… - Blood, The Journal …, 2022 - ashpublications.org
A large amount of circumstantial evidence has accumulated suggesting that Toll-like
receptor (TLR) signals are involved in driving chronic lymphocytic leukemia (CLL) cell …
receptor (TLR) signals are involved in driving chronic lymphocytic leukemia (CLL) cell …
Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies
The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a
number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse …
number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse …